Sarepta Therapeutics (SRPT) announced early but encouraging results Wednesday from its second gene therapy program targeting a rare, muscle-wasting disease.
A one-time infusion of a corrective gene, delivered using an engineered virus, produced meaningful levels of a protein — an average of 51 percent — suggesting (but not yet proving) that muscle function can be improved, Sarepta said.
The three patients enrolled in the clinical trial have a form of limb-girdle muscular dystrophy, an inherited disorder that causes muscles around the hips and shoulders to weaken and atrophy over time.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.